New peptide injection could get athletes back in the game faster
NCT ID NCT07437547
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a daily injection of BPC 157, a synthetic peptide, can help people with a moderate hamstring tear heal faster. 120 adults aged 18-45 with a recent MRI-confirmed grade II strain will receive either BPC 157 or a placebo for 14 days, plus standard rehab. The main goals are to see how quickly they can return to sport and how much the muscle injury shrinks on MRI.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- BPC 157 (a synthetic peptide given as a daily injection for 14 days)
- What this could lead to
- If it works, this could provide a new treatment to help athletes and active people recover faster from hamstring injuries.
- What could go wrong
- This is an early Phase 2 trial with only 120 people, so results may not apply to everyone. The peptide is investigational and its safety and effectiveness are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Feb 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 to 45 years. * Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening. * MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion. * Pre-injury physical activity \>= 3 sessions/week or participation in organized recreational sport. * Willingness to follow the standardized rehabilitation protocol and attend all study visits. * For participants of childbearing potential: negative pregnancy test at baseline and agreement to use effective contraception during dosing and for 30 days after last dose. Exclusion Criteria: * Grade III hamstring tear, tendon avulsion, or injury requiring surgical management. * Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment. * Prior hamstring strain on the index limb within the past 6 months. * Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides/growth factors within 30 days prior to screening. * Known bleeding disorder or current therapeutic anticoagulation. * Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk. * Known allergy or hypersensitivity to components of the investigational product or placebo. * Pregnant or breastfeeding. * Current participation in another interventional clinical study or participation within 30 days prior to screening. * Currently subject to a formal anti-doping testing program (e.g., WADA/USADA-aligned) where use of an investigational peptide could create a regulatory conflict, unless explicitly approved by the relevant authority
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hamstring muscle strain are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.